Company Focus
Chiesi Farmaceutici
Latest Chiesi Farmaceutici News
Pharmaceutical
Family-controlled Italian drugmaker Chiesi Group has announced financial results for the six months ended June 30, 2025. 16 September 2025
Related News
Insights
Company Spotlight
A biopharma company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.
Latest News & Features of interest to Chiesi Farmaceutici
Pharmaceutical
Danish pharma major Novo Nordisk has presented new post-hoc analyses from the Phase III REDEFINE 1 trial evaluating CagriSema (cagrilintide/semaglutide), an investigational injectable combination treatment for overweight or obese adults, and effects on well-known cardiovascular (CV) risk factors, including hypertension and systemic inflammation. 7 November 2025
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca closed Thursday’s trading 3% higher, as investors digested its third quarter financial results. 6 November 2025
Biotechnology
US biopharma company Ultragenyx Pharmaceutical today announced the sale, for $400 million, of an additional 25% of the company’s royalty interest from Kyowa Kirin on the future sales of Crysvita (burosumab) in the USA and Canada to OMERS, one of Canada’s largest defined benefit pension plans. 6 November 2025
Biotechnology
California, USA-based clinical-stage biotech Braveheart Bio has announced its launch with $185 million in Series A financing, which will support development of an investigation treatment for hypertrophic cardiomyopathy. 6 November 2025
Biotechnology
Shares of US clinical-stage biopharma Biohaven plunged more than 40% to $8.34 yesterday, after it announced that it has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of Vyglxia (troriluzole) for the treatment of spinocerebellar ataxia (SCA). 6 November 2025
Biotechnology
US biopharma firm Viridian Therapeutics today announced the successful submission of its biologics license application (BLA) to the US Food and Drug Administration (FDA) for veligrotug, the company’s investigational therapy for the treatment of thyroid eye disease (TED). 5 November 2025
Pharmaceutical
US pharma giant Pfizer reported financial results for the third quarter of 2025 on Tuesday. 4 November 2025
Pharmaceutical
US pharma major Eli Lilly has revealed plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. 4 November 2025
Pharmaceutical
US biopharma Vertex Pharmaceuticals has reported consolidated financial results for the third quarter of 2025 and refined its full year financial guidance. 4 November 2025
Pharmaceutical
Swiss specialty drugmaker Santhera Pharmaceuticals saw its shares rise 5.8% to 10.90 francs today, after it reported positive top-line results from an analysis of long-term data, including first assessments from the ongoing, open-label, multicenter GUARDIAN study evaluating Agamree (vamorolone) in patients with Duchenne muscular dystrophy (DMD). 4 November 2025
Latest In Brief for Chiesi Farmaceutici
Pharmaceutical
Swiss specialty drugmaker Santhera Pharmaceuticals has announced the signing of an exclusive agreement with Biomedica for the distribution of Agamree (vamorolone) in Russia, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. 9 October 2025
Latest Relevant Ones To Watch News
M&A news last week featured Swiss pharma giant Novartis announcing it has agreed to acquire rare disease drug developer Avidity Biosciences for $12 billion, and Denmark’s Novo Nordisk surprised Wall Street, disclosing an unsolicited takeover bid for US obesity drug developer Metsera, which is already the subject of an agreed bid from Pfizer. Research news of note saw US drugmaker Intellia suffer a setback with its nexiguran ziclumeran, pausing a Phase III trial following identification of liver toxicity. Also, Akebia Therapeutics announced it will discontinue plans to expand use of its anemia drug Vafseo following discussions with the US Food and Drug Administration (FDA). 2 November 2025
27 October 2025
14 October 2025
8 October 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze